ワクチンアジュバント市場- 世界の産業規模、シェア、動向、機会、予測、製品別、タイプ別、用途別、地域別セグメント、競合、2020年～2030年

ワクチンアジュバントの世界市場規模は2024年に7億2,000万米ドルとなり、2030年までのCAGRは6.56%で、予測期間中に力強い成長が予測されています。

ワクチンアジュバントの世界市場は、より広範なヘルスケア産業の重要な構成要素であり、ワクチンの有効性を高め、世界の予防接種の取り組みを強化する上で極めて重要な役割を果たしています。ワクチンアジュバントはワクチンに添加される物質で、より強力で長持ちする免疫反応を刺激し、最終的に感染症に対する予防効果を向上させます。この市場は、ウイルス感染症、細菌性疾患、新興パンデミックなど、さまざまな疾病と闘うためのワクチン需要の増加により、近年大きな成長を遂げています。

市場促進要因

感染症の脅威の高まり

主な市場課題

規制上のハードル

主要市場動向

消費者市場の拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のワクチンアジュバント市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（アジュバント乳剤、病原体成分、サポニン系アジュバント、粒子状アジュバント、その他のアジュバント）
  • タイプ別（ヒト用ワクチンアジュバント、動物用ワクチンアジュバント）
  • 用途別（調査用途、商用用途）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 製品別
  • タイプ別
  • 用途別
  • 地域別

第5章 アジア太平洋地域のワクチンアジュバント市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • タイプ別
  • 用途別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のワクチンアジュバント市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のワクチンアジュバント市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のワクチンアジュバント市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのワクチンアジュバント市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界のワクチンアジュバント市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Dynavax Technologies
• Croda International Plc
• Gsk Plc
• Novavax
• Spi Pharma（A Subsidiary of Associated British Foods Plc）
• Agenus Inc.
• Phibro Animal Health Corporation
• Aurorium（Formerly Vertellus）
• Merck Kgaa
• Vaxine Pty Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Vaccine Adjuvants Market was valued at USD 0.72 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.56% through 2030. The Global Vaccine Adjuvants Market is a critical component of the broader healthcare industry, playing a pivotal role in enhancing the efficacy of vaccines and bolstering global immunization efforts. Vaccine adjuvants are substances added to vaccines to stimulate a stronger and longer-lasting immune response, ultimately leading to improved protection against infectious diseases. This market has witnessed significant growth in recent years, driven by the increasing demand for vaccines to combat a wide range of diseases, including viral infections, bacterial illnesses, and emerging pandemics.

Key Market Drivers

Rising Infectious Disease Threats

The Global Vaccine Adjuvants Market is experiencing a notable upswing, and one of the primary driving forces behind this growth is the persistent and escalating threat posed by infectious diseases. In recent years, the world has witnessed a series of infectious disease outbreaks and pandemics that have underscored the critical importance of vaccination and vaccine adjuvants in safeguarding public health. These threats have led to a surge in demand for adjuvants, which play a pivotal role in enhancing the efficacy of vaccines and ensuring rapid and robust immune responses. For instance, according to the World Health Organization, infectious diseases are responsible for over 17 million deaths annually. Over the past two decades, 30 new infectious diseases have emerged, posing significant global health challenges and highlighting the urgent need for innovative prevention, treatment, and surveillance strategies.

Key Market Challenges

Regulatory Hurdles

One of the most formidable challenges for vaccine adjuvants is the arduous journey through the regulatory approval process. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require extensive preclinical and clinical data to demonstrate the safety and efficacy of new adjuvants. These rigorous requirements can significantly lengthen the timeline from development to market approval, delaying adjuvant availability and increasing development costs.

Regulatory requirements for vaccine adjuvants vary from one country or region to another. This lack of harmonization can create a complex and fragmented landscape for manufacturers seeking global approval. Adhering to multiple sets of regulations necessitates additional resources and can discourage investment in adjuvant research and development. Regulatory agencies often provide limited guidance or specific pathways for the approval of adjuvants. Manufacturers are left to navigate the regulatory process with minimal clear direction, which can result in uncertainty and potential missteps during development and submission. Clarity and consistent guidelines would be instrumental in streamlining the approval process.

Key Market Trends

Expanding Consumer Markets

The Global Vaccine Adjuvants Market is experiencing a significant boost, thanks to the expansion of consumer markets across the globe. As public awareness about the importance of vaccines continues to grow, the demand for effective immunization has surged, propelling the need for vaccine adjuvants. Several factors contribute to the expansion of consumer markets and their positive impact on the vaccine adjuvants market. Rising global populations, particularly in emerging economies, are driving an increased demand for vaccines. As more people seek protection against infectious diseases, vaccine manufacturers are ramping up their production. Vaccine adjuvants play a pivotal role in enhancing the efficacy of vaccines, making them more attractive to a broader consumer base.

Furthermore, the prevalence of infectious diseases remains a global concern. Outbreaks and pandemics like the COVID-19 crisis have highlighted the critical need for vaccines to prevent and control the spread of diseases. This heightened awareness of infectious disease threats has motivated individuals and governments to invest in vaccination programs, further fueling the demand for adjuvanted vaccines.

Key Market Players

• Dynavax Technologies
• Croda International Plc
• Gsk Plc
• Novavax
• Spi Pharma (A Subsidiary of Associated British Foods Plc)
• Agenus Inc.
• Phibro Animal Health Corporation
• Aurorium (Formerly Vertellus)
• Merck Kgaa
• Vaxine Pty Ltd

Report Scope:

In this report, the Global Vaccine Adjuvants Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vaccine Adjuvants Market, By Product:

• Adjuvant Emulsions
• Pathogen Components
• Saponin-Based Adjuvants
• Particulate Adjuvants
• Other Adjuvants

Vaccine Adjuvants Market, By Type:

• Human Vaccine Adjuvants
• Veterinary Vaccine Adjuvants

Vaccine Adjuvants Market, By Application:

• Research Applications
• Commercial Applications

Vaccine Adjuvants Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vaccine Adjuvants Market.

Available Customizations:

Global Vaccine Adjuvants Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Vaccine Adjuvants Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Product (Adjuvant Emulsions, Pathogen Components, Saponin-Based Adjuvants, Particulate Adjuvants, Other Adjuvants)
  • 4.2.2. By Type (Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants)
  • 4.2.3. By Application (Research Applications, Commercial Applications)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Product
  • 4.3.2. By Type
  • 4.3.3. By Application
  • 4.3.4. By Region

5. Asia Pacific Vaccine Adjuvants Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product
  • 5.2.2. By Type
  • 5.2.3. By Application
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Vaccine Adjuvants Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Product
      • 5.3.1.2.2. By Type
      • 5.3.1.2.3. By Application
  • 5.3.2. India Vaccine Adjuvants Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Product
      • 5.3.2.2.2. By Type
      • 5.3.2.2.3. By Application
  • 5.3.3. Australia Vaccine Adjuvants Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Product
      • 5.3.3.2.2. By Type
      • 5.3.3.2.3. By Application
  • 5.3.4. Japan Vaccine Adjuvants Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Product
      • 5.3.4.2.2. By Type
      • 5.3.4.2.3. By Application
  • 5.3.5. South Korea Vaccine Adjuvants Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Product
      • 5.3.5.2.2. By Type
      • 5.3.5.2.3. By Application

6. Europe Vaccine Adjuvants Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Type
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Vaccine Adjuvants Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Application
  • 6.3.2. Germany Vaccine Adjuvants Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Application
  • 6.3.3. Spain Vaccine Adjuvants Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Application
  • 6.3.4. Italy Vaccine Adjuvants Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Type
      • 6.3.4.2.3. By Application
  • 6.3.5. United Kingdom Vaccine Adjuvants Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Type
      • 6.3.5.2.3. By Application

7. North America Vaccine Adjuvants Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Type
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Vaccine Adjuvants Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Application
  • 7.3.2. Mexico Vaccine Adjuvants Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Application
  • 7.3.3. Canada Vaccine Adjuvants Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Application

8. South America Vaccine Adjuvants Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Type
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Vaccine Adjuvants Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Application
  • 8.3.2. Argentina Vaccine Adjuvants Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Application
  • 8.3.3. Colombia Vaccine Adjuvants Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Application

9. Middle East and Africa Vaccine Adjuvants Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Type
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Vaccine Adjuvants Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Application
  • 9.3.2. Saudi Arabia Vaccine Adjuvants Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Application
  • 9.3.3. UAE Vaccine Adjuvants Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Application
  • 9.3.4. Egypt Vaccine Adjuvants Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product
      • 9.3.4.2.2. By Type
      • 9.3.4.2.3. By Application

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Vaccine Adjuvants Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Dynavax Technologies
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Croda International Plc
• 14.3. Gsk Plc
• 14.4. Novavax
• 14.5. Spi Pharma (A Subsidiary of Associated British Foods Plc)
• 14.6. Agenus Inc.
• 14.7. Phibro Animal Health Corporation
• 14.8. Aurorium (Formerly Vertellus)
• 14.9. Merck Kgaa
• 14.10. Vaxine Pty Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer